Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Lymphoma 113Leukemia 80Precursor Cell Lymphoblastic Leukemia-Lymphoma 61Lymphoma, Non-Hodgkin 59Multiple Myeloma 56Leukemia, Myeloid, Acute 56Lymphoma, Large B-Cell, Diffuse 55Hodgkin Disease 48Myelodysplastic Syndromes 43Burkitt Lymphoma 43Lymphoma, Follicular 41Leukemia, Lymphocytic, Chronic, B-Cell 41Lymphoma, Mantle-Cell 40Breast Neoplasms 35Lymphoma, Large-Cell, Immunoblastic 34Sarcoma 27Neoplasms, Plasma Cell 27Central Nervous System Neoplasms 25Lymphoma, B-Cell, Marginal Zone 24Dendritic Cell Sarcoma, Interdigitating 19Recurrence 18Leukemia, Myelogenous, Chronic, BCR-ABL Positive 18Ovarian Neoplasms 16Neuroblastoma 16Myeloproliferative Disorders 16Leukemia, Myeloid, Chronic-Phase 16Leukemia, Myeloid, Accelerated Phase 15Congenital Abnormalities 15Neutropenia 13Lung Neoplasms 13

Interventions

cediranib 3perifosine 2pembrolizumab 2pazopanib 2atezolizumab 2Sunitinib 2Specimen Handling 2Loperamide 2selinexor 1sargramostim 1romidepsin 1cabozantinib 1brostallicin 1atropine sulfate-diphenoxylate hydrochloride drug combination 1Warfarin 1Vitamin B 6 1Trabectedin 1Thyroxine 1Temozolomide 1Radiotherapy, Intensity-Modulated 1Radiation Dose Hypofractionation 1Pyridoxine 1Promethazine 1Prochlorperazine 1Polymerase Chain Reaction 1Petrolatum 1Neoadjuvant Therapy 1Mass Spectrometry 1Lorazepam 1Immunoglobulin G 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Sarcoma, Alveolar Soft Part × Filgrastim × Clear all
NCT01391962 2026-02-02

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
34 enrolled 22 charts
Sarcoma

Sarcoma, Alveolar Soft Part

Data powered by HemOnc (CC BY 4.0) Colophon âš¡